PRESS RELEASE

Geneva, June 02, 2025,

TEOXANE ANNOUNCES PUBLICATION OF THE RESULTS OF A PROSPECTIVE OBSERVATIONAL REAL-WORLD STUDY ON A HYALURONIC ACID-BASED DERMAL FILLER USED FOR PERIORBITAL REJUVENATION.

Teoxane announces the publication of new clinical evidence supporting the efficacy and safety of TEOSYAL® PureSense Redensity 2 (R2), a hyaluronic acid-based dermal filler specifically designed for periorbital rejuvenation, a key area in facial aesthetics and aging perception.

Study Methodology

Led by Teoxane Clinical Department, the EYELIGHT study was designed as a prospective, prospective, observational clinical trial, conducted across two centers in the UK and one in France, and involving **136 subjects** treated between May 2020 and February 2021. One of the investigators is Dr Tahera Bhojani-Lynch, a renowned ophthalmologist and aesthetic specialist, practicing in the UK.

The indication/s, product and injection characteristics—including volume, depth, and technique—were left to the discretion of the investigator in respect of the observational nature of EYELIGHT. This research approach ensured the collection of routine evidence on the use of R2 beyond its initially approved indication, offering valuable insights into the actual utilization of the product in clinical practice. Nevertheless, the publication focused only on the periorbital indication.

- **Primary Efficacy Endpoint:** Global Aesthetic Improvement Scale (GAIS) score assessed at 3 months post-treatment by both the investigator and the subject, combining data across all indications.
- **Secondary Endpoints**: Investigator and subject satisfaction, GAIS assessments at 6, 9, and 12 months, and safety evaluations (Common Treatment Responses [CTRs] and Adverse Event [AEs]).

Primary Endpoint:

Over the study period, 958 injections were administered, with 451 injections (47.1%) performed using TEOSYAL® PureSense Redensity 2 alone across various periorbital regions. Of these, 89 (35.3%) targeted the tear trough, 61 (24.2%) the palpebromalar groove, 45 (17.9%) the outer canthus, 38 (15.1%) the crow's feet, and 19 (7.5%) the brow.

Over 75% of treated areas showed visible global aesthetic improvement (GAIS) after 3 months according to both the injector and subject meeting the primary endpoint with the predefined 70% threshold

. Precisely, a significant aesthetic improvement was observed in 84.3% of subjects (tear trough), 77% (palpebromalar groove), 81.6% (crow's feet), 78.9% (brow area) and 78.4% (outer canthus).

A total of 85% of subjects were either 'satisfied' or 'very satisfied' with treatment after 3 months in the tear trough, 83% in the palpebromalar groove, 92% in the outer canthal lift, and 69% in the brow. Almost all injectors were 'satisfied' with R2 treatment in the periorbital area (99%), and all of them found the product 'easy to inject'.
Additionally, all subjects were deemed improved post-injection by the investigator for all indications, with at least 82% at month 9 and 60% of about half of the initial patients still showing improvement at month 12.

Safety Endpoints: Excellent Tolerability and Minimal Adverse Events

- Across 958 injections, all common treatment responses (CTRs) were mild to moderate and resolved within one month.
- Only **2.9%** (4 cases) of the 136 subjects experienced adverse events, with only one classified as device-related (mild, self-limiting edema that **resolved in 28 days**).
- **No severe AEs or long-term complications** were reported, reinforcing the strong safety profile of Redensity 2.
- Pain levels remained low to moderate, with an average VAS score of 20-30 mm immediately post-injection, **dropping to near zero** by the end of the consultation.

Key Findings:

- **Primary Indication & Expanded Use**: The tear trough was confirmed as the primary treatment area, but Redensity® 2 was also effectively used in other periorbital regions including the palpebromalar groove, crow's feet, outer canthal area, and brow.

- **Sustained Aesthetic Outcomes**: A significant improvement in the whole periorbital region was observed, with results maintained up to 12 months post-injection.

- **High Satisfaction and Ease of Use**: **84.3%** of subjects reported satisfaction with their aesthetic outcomes, and **99%** of practitioners found the product easy to use with a positive injection experience.

- **Minimal Touch-Ups Needs**: Only 17.6% of subjects required a touch-up during the 12-month follow-up period, reflecting both the filler's longevity and effective tissue integration.

- **Excellent Safety Profile**: All CTRs were mild to moderate and transient, with no serious AE reported, confirming the safety of Redensity® 2 in the delicate periorbital area.
-

"*Keeping the periorbital region looking youthful is deemed essential in facial aesthetics, and the ageing appearance of this area is of frequent concern amongst patients seeking facial*

rejuvenation. These findings reinforce the decade-long clinical success of TEOSYAL® PureSense Redensity 2 for tear trough correction while expanding its recognized efficacy across the entire periorbital region" said Dr. Tahera Bhojani-Lynch. "*The results highlight Redensity 2's ability to provide a comprehensive solution able to address key periorbital concerns and extends its range of use beyond the under eye, for safe and effective soft tissue correction in the wider eye.*"

Teoxane remains committed to advancing aesthetic medicine through rigorous scientific research and innovation. The EYELIGHT study provides invaluable clinical insights for practitioners, demonstrating TEOSYAL® PureSense Redensity 2 use beyond the tear trough, showing effectiveness and safety in the whole periorbital area.

About TEOSYAL® PureSense Redensity 2

TEOSYAL® PureSense Redensity 2 is a hyaluronic acid-based dermal filler combining both crosslinked and non-cross-linked HA, specifically designed for periorbital rejuvenation, offering natural-looking results with a strong safety profile. Redensity 2 combines high elasticity, which allows the gel to adapt harmoniously to the anatomy of the eye contour providing a natural-looking result, with low resistance, enabling the filling of dark circles while minimizing the risk of puffiness. Its low hygroscopic properties allow for minimal water absorption and swelling.

About Teoxane

Founded by Valérie Taupin in 2003, Teoxane Laboratories is the leading Swiss expert in the science of hyaluronic acid. For 20 years, Teoxane has pushed innovation, pioneered the future of aesthetics, and opened the door to a new world of natural, expressive, and emotive beauty. The company was founded on a singular vision: to unlock the possibilities of aesthetic treatments through high-performance dermal filler and dermocosmetics, rooted in rigorous scientific research. By consistently listening, educating and laying the groundwork for a safer industry, Teoxane has shaped a new era in aesthetic medicine where small acts of beauty create dramatic changes in the lives of patients and healthcare practitioners alike.

www.teoxane.com

Press Contact
Tiffanie Ereno – PR & Communications Manager :
t.ereno@teoxane.com
press@teoxane.com